Free Trial

Can-Fite BioPharma (CANF) Competitors

Can-Fite BioPharma logo
$0.98 -0.03 (-2.97%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$0.98 +0.01 (+0.51%)
As of 07/25/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CANF vs. ERNA, PMN, LPTX, BFRG, SNPX, NEUP, FLGC, NERV, HOOK, and IMCC

Should you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Ernexa Therapeutics (ERNA), Promis Neurosciences (PMN), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), Synaptogenix (SNPX), Neuphoria Therapeutics (NEUP), Flora Growth (FLGC), Minerva Neurosciences (NERV), HOOKIPA Pharma (HOOK), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry.

Can-Fite BioPharma vs. Its Competitors

Ernexa Therapeutics (NASDAQ:ERNA) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Ernexa Therapeutics has a beta of 5.3, indicating that its stock price is 430% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Can-Fite BioPharma has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%.

Company Net Margins Return on Equity Return on Assets
Ernexa Therapeutics-7,652.75% N/A -285.71%
Can-Fite BioPharma N/A N/A N/A

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for Can-Fite BioPharma. Ernexa Therapeutics' average media sentiment score of 1.87 beat Can-Fite BioPharma's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Ernexa Therapeutics Very Positive
Can-Fite BioPharma Neutral

Can-Fite BioPharma has higher revenue and earnings than Ernexa Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ernexa Therapeutics$580K24.74-$44.54M-$8.31-0.23
Can-Fite BioPharma$674K5.15-$7.63M-$1.79-0.55

Can-Fite BioPharma has a consensus price target of $14.00, suggesting a potential upside of 1,328.57%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Ernexa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Can-Fite BioPharma beats Ernexa Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Can-Fite BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CANF vs. The Competition

MetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$3.47M$789.68M$5.70B$21.03B
Dividend YieldN/A4.84%4.58%3.59%
P/E Ratio-0.551.4128.3928.45
Price / Sales5.1524.88430.0871.66
Price / CashN/A19.5636.2222.92
Price / Book0.566.918.674.68
Net Income-$7.63M-$4.13M$3.25B$995.51M
7 Day Performance-5.31%1.01%4.30%1.65%
1 Month Performance-5.31%3.65%10.57%4.54%
1 Year Performance-73.58%9.83%35.68%10.00%

Can-Fite BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CANF
Can-Fite BioPharma
1.9841 of 5 stars
$0.98
-3.0%
$14.00
+1,328.6%
-71.7%$3.47M$674K-0.558
ERNA
Ernexa Therapeutics
1.0615 of 5 stars
$1.96
-1.0%
N/A-92.8%$14.58M$580K-0.2410Positive News
Gap Up
PMN
Promis Neurosciences
2.9604 of 5 stars
$1.12
+154.5%
$4.33
+286.9%
-51.1%$14.39MN/A-22.405News Coverage
Analyst Revision
High Trading Volume
LPTX
Leap Therapeutics
2.0967 of 5 stars
$0.34
-1.5%
$3.38
+895.6%
-83.4%$14.26MN/A-0.2040Positive News
Gap Down
BFRG
Bullfrog AI
0.4298 of 5 stars
$1.50
-0.7%
N/A-52.8%$14.22M$60K-1.854High Trading Volume
SNPX
Synaptogenix
0.037 of 5 stars
$10.11
+7.6%
N/A+115.0%$14.05MN/A-1.004High Trading Volume
NEUP
Neuphoria Therapeutics
1.8629 of 5 stars
$7.70
+3.4%
$21.00
+172.7%
N/A$14.01M$10K0.00N/ANews Coverage
Positive News
Analyst Upgrade
FLGC
Flora Growth
2.6337 of 5 stars
$0.65
+4.4%
$4.00
+517.3%
-46.5%$14M$59.51M-0.66280Positive News
NERV
Minerva Neurosciences
4.4029 of 5 stars
$1.95
-2.0%
$5.00
+156.3%
-31.7%$13.92MN/A2.389Positive News
HOOK
HOOKIPA Pharma
3.0658 of 5 stars
$1.04
-8.8%
$4.50
+332.7%
-85.4%$13.90M$43.95M-0.18160News Coverage
High Trading Volume
IMCC
IM Cannabis
0.1208 of 5 stars
$3.04
-11.1%
N/A+13.3%$13.83M$39.44M-4.75340News Coverage
Analyst Upgrade
Gap Down

Related Companies and Tools


This page (NYSE:CANF) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners